CATALYSIS
Catalysis, Lead and Learn, and CHU UCL Namur, today announced the agenda for the Third Lean Healthcare Transformation Summit – Europe . The Summit, which includes optional pre-summit workshops, keynote addresses and learning sessions, will be held at Dolce La Hulpe, in Brussels, Belgium, March 13-15. Optional post-session gemba site visits are scheduled for March 16. Online registration for the Summit is available at www.lead-and-learn.eu/en/
“The Lean Healthcare Transformation Summit in Europe gives physicians, administrators and hospital leaders an opportunity to learn from globally recognized experts who have first-hand expertise in lean healthcare transformation,” said Rachel Regan, director of events at Catalysis. “The agenda is packed with speakers from across the world who are excited to help organizations begin their transformation journeys.”
Designed for healthcare leaders, with tracks for physicians, beginners, and advanced leaders and practitioners who want to learn how to transform their healthcare organizations, the Summit provides attendees with two days of interactive learning sessions and in-depth pre-Summit workshops. The post-Summit includes optional hospital gemba visits at the CHU UCL Namur Godinne site, Saint Luc Academic Hospital and Antwerp University Hospital near Namur.
“We are excited to participate in this year’s Lean Healthcare Transformation Summit-Europe, and share the many successes that hospitals and clinics in Europe have to offer,” said Patrick De Coster, MD, from CHU Dinant Godinne. “Teaching lean principles to other hospital administrators, physicians and staff helps to create healthcare value in Europe and, ultimately, enhance patient outcomes.”
The Summit features globally recognized experts renowned for their experience in healthcare transformation. Learning sessions are offered in a variety of languages, including English, French, and Dutch.
About Catalysis
Catalysis inspires healthcare leaders and accelerates change. With a focus on experiential education, Catalysis helps healthcare leaders in the United States and Europe create system-wide, transformative change. We believe in care delivery designed around the patient, payment and incentives based on value and outcomes, and transparency of performance (quality and cost). Founded in 2008, Catalysis is a not for profit with a mission to help create more healthcare value in the industry. Learn more at: createvalue.org .
About Lead and Learn
Lead and Learn is a non-profit founded by Patrick De Coster and Ariane Bouzette, with support from CHU UCL Namur. The organization’s mission is to transform the healthcare systems around Europe and grow the lean healthcare community in the region. For more information, visit: lead-and-learn.eu/en/
About CHU UCL Namur
The Dinant Godinne CHU | UCL Namur and the Clinique et Maternité Sainte-Elisabeth merged in 2016. Located in the province of Namur, organization has locations in Dinant, Godinne and Sainte-Elisabeth. In addition to hospital services, CHU UCL Namur provides housing for senior citizens and offers early childhood care. With more than 4,500 employees, UCL Namur University offers comprehensive care and services to its patients.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170212005009/en/
Contact:
Catalysis
Chuck Grothaus, 612-770-0026
chuck.grothaus@c2comms.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release
Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison
Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release
Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom